Completed PHASE2 NCT00321633

Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer

A Randomized Phase II Pilot Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic Genetic Breast Cancer [BRCA Trial]

Sponsor: University College London Hospitals

Conditions Breast Cancer Hereditary Breast/Ovarian Cancer (brca1, brca2) brca1 Mutation Carrier brca2 Mutation Carrier

Interventions carboplatin docetaxel

Updated 6 times since 2017 Last updated: Aug 23, 2013 Started: Sep 30, 2005 Primary completion: Sep 30, 2009

This PHASE2 trial investigates Breast Cancer and Hereditary Breast/Ovarian Cancer (brca1, brca2) and is currently completed. University College London Hospitals leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University College London Hospitals

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Beersheba, Israel , Cambridge, United Kingdom , Cardiff, United Kingdom , Edinburgh, United Kingdom , Exeter, United Kingdom , Hampstead, London, United Kingdom , Leeds, United Kingdom , Lisbon, Portugal , London, United Kingdom and 13 more locations